Oncothyreon Inc. (ONTY) in Focus: Stock Up 5.2% - Tale of the Tape
02 Décembre 2013 - 2:44PM
Zacks
Oncothyreon Inc.
(ONTY) was a big mover last session, as the company saw its shares
rise a little over 5% on the day. This rise can be attributable to
solid volume too with far more shares changing hands than in a
normal session. This continues the most recent uptrend of the
company, as the stock is now up 14.04% in the past one-month time
frame.
In the last 30 days, the company witnessed 2 upward and downward
estimate revisions each while the Zacks Consensus Estimate has
remained unchanged in the same period. However, the recent price
action is encouraging, so make sure to keep a close watch on this
firm in the near future.
Oncothyreon currently has a Zacks Rank #3 (Hold) while its Earnings
ESP is positive.
Some better-ranked biopharmaceutical stocks include Heska
Corporation (HSKA), Actelion Ltd. (ALIOF)
and AMAG Pharmaceuticals, Inc. (AMAG). All these
stocks hold a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30
Days. Click to get this free report >>
ACTELION LTD (ALIOF): Get Free Report
AMAG PHARMA INC (AMAG): Free Stock Analysis Report
HESKA CORP (HSKA): Free Stock Analysis Report
ONCOTHYREON INC (ONTY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
(USOTC:ALIOF)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
(USOTC:ALIOF)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about (OTCMarkets): 0 recent articles
Plus d'articles sur Actelion Ltd. (PC)